AstraZeneca has signed a drug discovery collaboration and licensing agreement with insitro to apply artificial intelligence ...
President Trump’s Most-Favored Nation (MFN) initiative continues to impact the industry. Most recently, the deadline passed ...
Why “we’re safe” is the most dangerous assumption in medical benefit commercialization. There is a conversation happening in boardrooms and brand planning cycles across the pharmaceutical industry ...
Pharmaceutical Executive spoke with Marc Wagner, an FDA and life sciences attorney at Fox Rothschild, about the manufacturing ...
After months of prodding, the European Medicines Agency (EMA) and member states of the European Union have begun taking ...
The FDA approved Enspryng (satralizumab) on Oct. 16 for adults with thyroid eye disease (TED). 1 Roche describes the ...
Roche licenses Rona Therapeutics’ ALK7-targeting RNAi candidate for obesity, while Pfizer partners with Enodia Therapeutics ...
Fox Rothschild's Mark Wagner on why scaling drug production is so slow — overseas API sourcing, supplier qualification, and ...
In today’s Pharmaceutical Executive Daily, Gilead and Vir Biotechnology enter a collaboration worth up to $1.87 billion to ...
MERGE's Pat McGloin on why pharma AI fails when strategy follows technology — and why the brilliant basics still have to come ...
Drug shortages remain a difficult to fix issue for the pharma industry and are an issue that can have devastating results.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended granting marketing authorization in the European Union for Eli Lilly’s Foundayo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results